SCHEMBL4965700

SCHEMBL4965700

O=C(NCC1COc2ccccc2O1)C1(Sc2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
GAA P10253 1/20 0.64
HPGD P15428 4/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
MTNR1A P48039 1/20 0.58
ALDH1A1 P00352 5/20 0.56
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.56
AIMP2 Q13155 4/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
MAPK1 P28482 1/20 0.55
ALOX12 P18054 2/20 0.53
CYP3A4 P08684 1/20 0.53
GLA P06280 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22393113 0.78 HPGD (0.76) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL1567604 0.76 MTNR1A (0.76) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL21348630 0.75 MTNR1A (0.70) HPGDNPC1RAB9ASMN1; SMN2MTNR1A
SCHEMBL21416050 0.75 MTNR1A (0.70) HPGDNPC1RAB9ASMN1; SMN2MTNR1A
SCHEMBL3141006 0.74 MTNR1A (0.62) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL7202212 0.74 MTNR1A (1.00) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL20509853 0.74 KDM4E (0.59) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL30267488 0.74 KDM4E (0.59) KDM4EGAAHPGDNPC1RAB9A
SCHEMBL4963017 0.74 KDM4E (0.76) KDM4EGAAHPGDNPC1RAB9A
Hydrochloric Acid SCHEMBL11028253 0.73 MTNR1A (0.97) HPGDNPC1RAB9ASMN1; SMN2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP claimed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 KDM4E 3590/4885GAA 558/4885HPGD 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.